Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Povetacicept · ALPN-303

Fusion protein · Antagonist of APRIL (TNFSF13) and BAFF (TNFSF13B) · developed by Vertex Pharmaceuticals

Phase 2/3 Most advanced trial

VRTX Developer

1 Registered trials

What is Povetacicept?

Povetacicept is an affinity-optimized Fc fusion protein composed of an engineered TACI domain fused to human IgG Fc. It binds and inhibits APRIL and BAFF, blocking their interaction with cell membrane receptors including BCMA and BAFF-R. This inhibits B-cell proliferation, maturation, and immunoglobulin secretion, suppressing autoimmune responses. It is studied in primary membranous nephropathy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ALPN-303
Drug type: Fusion protein
Targets: APRIL (TNFSF13), BAFF (TNFSF13B), BCMA (TNFRSF17) (binding partner it blocks), BAFF-R (TNFRSF13C) (binding partner it blocks)
Mechanism: Antagonist of APRIL (TNFSF13) and BAFF (TNFSF13B)
Pathways: B-cell proliferation and maturation, immunoglobulin secretion, autoimmune response
Therapy area: Immunology, Renal & urology
Developer: Vertex Pharmaceuticals Incorporated (VRTX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII: EN2U82XV65

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07204275	Phase 2/3	Primary Membranous Nephropathy	Recruiting	VRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Primary Membranous Nephropathy

Other drugs acting on TNFSF13 / TNFSF13B

Atacicept FDA approved Telitacicept Phase 3 Tibulizumab Phase 2

More from Vertex Pharmaceuticals

Deutivacaftor FDA approved Elexacaftor FDA approved Exagamglogene Autotemcel FDA approved Ivacaftor FDA approved Suzetrigine FDA approved Tezacaftor FDA approved Vanzacaftor FDA approved Inaxaplin Phase 2/3 VX-017 Phase 3 VX-118 Phase 1 VX-264 Phase 1/2 VX-272 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the VRTX page.

Follow VRTX, the company behind Povetacicept

See VRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VRTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z